Jenny Christine Kienzler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jenny Christine Kienzler has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Javier Fandino
Department of Neurosurgery, Hirslanden Medical Center, 5001 Aarau, Switzerland
11 shared publications - Serge Marbacher
Department of Neurosurgery, Kantonsspital Aarau, 5001 Aarau, Switzerland
5 shared publications - Burkhard Becher
Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland
4 shared publications Javier Fandino
Hirslanden Med Ctr Aarau & Zurich, Dept Neurosurg, Aarau, Switzerland
4 shared publicationsSabrina Bäbler
Department of Neurosurgery, Kantonsspital Aarau, Tellstrasse, 5001, Aarau, Switzerland
4 shared publications- Alexander Lee
Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, USA
3 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by S. Karger AG in Neurodegenerative Diseases
- p. 1-11
Standardizing Normal Pressure Hydrocephalus Diagnosis: The Interdisciplinary Lausanne’s Protocol
Introduction: Idiopathic normal pressure hydrocephalus (iNPH) is a reversible neurological condition characterized by gait disorders, cognitive impairment, and urinary incontinence with ventriculomegaly at brain imaging. Due to the diagnostic complexity, we developed a structured multidisciplinary protocol to improve iNPH diagnosis. We present here the results of the first year after its implementation. Methods: A multidisciplinary team involving neurosurgeons, physical therapists, neuropsychologists, and neurologists at the Lausanne University Hospitals (Switzerland) organized a diagnostic path with the following steps: first neurological assessment at the Leenaards Memory Center, neuropsychological assessment, CSF tap test with physiotherapeutic evaluation before and 24 h after the CSF tap-test, post-CSF tap test interdisciplinary consultation with a neurosurgeon and a neurologist, and an interdisciplinary board. In case of neurosurgical treatment, interdisciplinary consultations took place at 6 weeks, 6 and 12 months. Results: This retrospective analysis included 86 patients (mean age: 76.26 ± 9.08 years; 32.6% female) evaluated between June 2024 and May 2025. Gait disorders were the most common complaint (94.2% of the patients) followed by cognitive (75.6%) and urinary (60.5%) complaints. After initial investigations, the Board evaluated 44 candidates and recommended ventriculoperitoneal shunting for 27 patients. So far, 16 patients have been operated. A total of 92% reported gait improvement at 6 weeks postoperative control. Patients above 80 years of age reported more often gait improvement than patients below 80 years. Conclusion: The Lausanne’s protocol demonstrates a feasible, structured, simplified, and efficient diagnostic pathway for iNPH, especially for the oldest patients.
- 6 July 2026
- Published by S. Karger AG in Neurodegenerative Diseases
- p. 1-11
Open AccessStandardizing Normal Pressure Hydrocephalus Diagnosis: The Interdisciplinary Lausanne’s Protocol
Introduction: Idiopathic normal pressure hydrocephalus (iNPH) is a reversible neurological condition characterized by gait disorders, cognitive impairment, and urinary incontinence with ventriculomegaly at brain imaging. Due to the diagnostic complexity, we developed a structured multidisciplinary protocol to improve iNPH diagnosis. We present here the results of the first year after its implementation. Methods: A multidisciplinary team involving neurosurgeons, physical therapists, neuropsychologists, and neurologists at the Lausanne University Hospitals (Switzerland) organized a diagnostic path with the following steps: first neurological assessment at the Leenaards Memory Center, neuropsychological assessment, CSF tap test with physiotherapeutic evaluation before and 24 h after the CSF tap-test, post-CSF tap test interdisciplinary consultation with a neurosurgeon and a neurologist, and an interdisciplinary board. In case of neurosurgical treatment, interdisciplinary consultations took place at 6 weeks, 6 and 12 months. Results: This retrospective analysis included 86 patients (mean age: 76.26 ± 9.08 years; 32.6% female) evaluated between June 2024 and May 2025. Gait disorders were the most common complaint (94.2% of the patients) followed by cognitive (75.6%) and urinary (60.5%) complaints. After initial investigations, the Board evaluated 44 candidates and recommended ventriculoperitoneal shunting for 27 patients. So far, 16 patients have been operated. A total of 92% reported gait improvement at 6 weeks postoperative control. Patients above 80 years of age reported more often gait improvement than patients below 80 years. Conclusion: The Lausanne’s protocol demonstrates a feasible, structured, simplified, and efficient diagnostic pathway for iNPH, especially for the oldest patients.
- Open Access
- 15 December 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 124
Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases
Purpose: Brain metastases (BrM) represent the most common intracranial malignancies and remain a major clinical challenge. Unlike glioblastoma (GBM), where immunotherapy has shown limited benefit, there are promising results for BrM. Nonetheless, several key aspects remain to be solved to amplify the success of these therapies, highlighting the potential of integrating immunotherapy with local strategies. This review focuses on therapeutic approaches for BrM, emphasizing the role of radiotherapy (RT) and focused ultrasound (FUS) in enhancing immunotherapy efficacy. Methods: We performed a narrative review of recent clinical studies addressing the interactions between the immune system, RT, and blood–brain barrier (BBB) modulation by FUS, with an emphasis on therapeutic strategies tested in BrM. Results: The success of immunotherapy in brain malignancies is hindered by the immunosuppressive tumor microenvironment (TME) and limited BBB penetration, as these treatments are administered systemically. RT synergizes with immunotherapy by promoting tumor antigen release and immune priming, which helps transiently overcome the immunosuppressive TME. However, excessive and prolonged antigen exposure may lead to T-cell exhaustion and checkpoint upregulation, which explains why sequential administration of stereotactic radiosurgery (SRS) followed by immunotherapy within a 2–4-week window enhances antitumor responses. Regarding the general difficulty for systemic drugs to access the brain, FUS emerges as a potent candidate for enabling transient BBB disruption, facilitating drug delivery, and biomarker access. Conclusion: Combining immunotherapy with SRS or FUS-mediated BBB modulation offers a promising path for improving outcomes in BrM. Future work must optimize these multimodal strategies while minimizing toxicity.
- 15 December 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (1) , 124
Open AccessSynergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases
Purpose: Brain metastases (BrM) represent the most common intracranial malignancies and remain a major clinical challenge. Unlike glioblastoma (GBM), where immunotherapy has shown limited benefit, there are promising results for BrM. Nonetheless, several key aspects remain to be solved to amplify the success of these therapies, highlighting the potential of integrating immunotherapy with local strategies. This review focuses on therapeutic approaches for BrM, emphasizing the role of radiotherapy (RT) and focused ultrasound (FUS) in enhancing immunotherapy efficacy. Methods: We performed a narrative review of recent clinical studies addressing the interactions between the immune system, RT, and blood–brain barrier (BBB) modulation by FUS, with an emphasis on therapeutic strategies tested in BrM. Results: The success of immunotherapy in brain malignancies is hindered by the immunosuppressive tumor microenvironment (TME) and limited BBB penetration, as these treatments are administered systemically. RT synergizes with immunotherapy by promoting tumor antigen release and immune priming, which helps transiently overcome the immunosuppressive TME. However, excessive and prolonged antigen exposure may lead to T-cell exhaustion and checkpoint upregulation, which explains why sequential administration of stereotactic radiosurgery (SRS) followed by immunotherapy within a 2–4-week window enhances antitumor responses. Regarding the general difficulty for systemic drugs to access the brain, FUS emerges as a potent candidate for enabling transient BBB disruption, facilitating drug delivery, and biomarker access. Conclusion: Combining immunotherapy with SRS or FUS-mediated BBB modulation offers a promising path for improving outcomes in BrM. Future work must optimize these multimodal strategies while minimizing toxicity.
- Open Access
- 28 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e51231
The Impact of Aspirin in Brain Tumor Surgery: To Stop or Not to Stop?
Given the lack of guidelines regarding perioperative management of neurosurgical patients taking antiplatelet medication, a break of aspirin intake for elective brain surgery is recommended. To the best of our knowledge, only three clinical studies have been published comparing re -bleeding rates in patients undergoing elective brain surgery with and without aspirin. We present a case of an 81 -year -old woman who was admitted for elective craniotomy and brain metastases resection. She presented with a right -sided hemianopsia for > two weeks and further investigation by magnetic resonance imaging (MRI) showed the left occipital lesion. For primary cardiovascular prevention, the patient was prescribed prophylactic low -dose aspirin 100 mg. A platelet function test on the day of admission detected highly pathological values. Surgery was scheduled the next day, and aspirin intake was paused. The platelet function test was repeated the morning before surgery. Interestingly, the test showed a 20% above -normal level platelet function. Craniotomy and tumor resection were performed in a routine fashion and no increased bleeding tendency was reported intraoperatively. Postoperatively, the right -sided hemianopsia was immediately regressive. MRI performed 24 hours after surgery demonstrated a complete tumor resection without any signs of rebleeding. The patient was discharged five days after surgery without any neurological deficits. The literature is limited and guidelines are missing on the topic of management of antiplatelet medication in elective brain surgery. As confirmed by the present case and a review of the literature, elective craniotomy and tumor resection under antiplatelet medication may be considered in certain cases with risk and benefit stratification. More data and randomized controlled trials are needed to confirm these findings.
- 28 December 2023
- Published by Springer Nature in Cureus
- Vol. 15 (12) , e51231
Open AccessThe Impact of Aspirin in Brain Tumor Surgery: To Stop or Not to Stop?
Given the lack of guidelines regarding perioperative management of neurosurgical patients taking antiplatelet medication, a break of aspirin intake for elective brain surgery is recommended. To the best of our knowledge, only three clinical studies have been published comparing re -bleeding rates in patients undergoing elective brain surgery with and without aspirin. We present a case of an 81 -year -old woman who was admitted for elective craniotomy and brain metastases resection. She presented with a right -sided hemianopsia for > two weeks and further investigation by magnetic resonance imaging (MRI) showed the left occipital lesion. For primary cardiovascular prevention, the patient was prescribed prophylactic low -dose aspirin 100 mg. A platelet function test on the day of admission detected highly pathological values. Surgery was scheduled the next day, and aspirin intake was paused. The platelet function test was repeated the morning before surgery. Interestingly, the test showed a 20% above -normal level platelet function. Craniotomy and tumor resection were performed in a routine fashion and no increased bleeding tendency was reported intraoperatively. Postoperatively, the right -sided hemianopsia was immediately regressive. MRI performed 24 hours after surgery demonstrated a complete tumor resection without any signs of rebleeding. The patient was discharged five days after surgery without any neurological deficits. The literature is limited and guidelines are missing on the topic of management of antiplatelet medication in elective brain surgery. As confirmed by the present case and a review of the literature, elective craniotomy and tumor resection under antiplatelet medication may be considered in certain cases with risk and benefit stratification. More data and randomized controlled trials are needed to confirm these findings.
- 11 December 2023
- Published by Wiley in European Journal of Immunology
- Vol. 54 (2) , e2250257
Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment
Malignant brain tumors lack effective treatment, that can improve their poor overall survival achieved with standard of care. Advancement in different cancer treatments has shifted the focus in brain tumor research and clinical trials toward immunotherapy‐based approaches. The investigation of the immune cell landscape revealed a dominance of myeloid cells in the tumor microenvironment. Their exact roles and functions are the subject of ongoing research. Current evidence suggests a complex interplay of tumor cells and myeloid cells with competing functions toward support vs. control of tumor growth.Here, we provide a brief overview of the three most abundant brain tumor entities: meningioma, glioma, and brain metastases. We also describe the field of ongoing immunotherapy trials and their results, including immune checkpoint inhibitors, vaccination studies, oncolytic viral therapy, and CAR‐T cells. Finally, we summarize the phenotypes of microglia, monocyte‐derived macrophages, border‐associated macrophages, neutrophils, and potential novel therapy targets.
- 11 December 2023
- Published by Wiley in European Journal of Immunology
- Vol. 54 (2) , e2250257
Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment
Malignant brain tumors lack effective treatment, that can improve their poor overall survival achieved with standard of care. Advancement in different cancer treatments has shifted the focus in brain tumor research and clinical trials toward immunotherapy‐based approaches. The investigation of the immune cell landscape revealed a dominance of myeloid cells in the tumor microenvironment. Their exact roles and functions are the subject of ongoing research. Current evidence suggests a complex interplay of tumor cells and myeloid cells with competing functions toward support vs. control of tumor growth.Here, we provide a brief overview of the three most abundant brain tumor entities: meningioma, glioma, and brain metastases. We also describe the field of ongoing immunotherapy trials and their results, including immune checkpoint inhibitors, vaccination studies, oncolytic viral therapy, and CAR‐T cells. Finally, we summarize the phenotypes of microglia, monocyte‐derived macrophages, border‐associated macrophages, neutrophils, and potential novel therapy targets.
- Open Access
- 8 December 2023
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 20, 100628
169P High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
- 8 December 2023
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 20, 100628
Open Access169P High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
- Open Access
- 1 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (17)
Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
In comparison with responses in recurrent glioblastoma (rGBM), the intracranial response of brain metastases (BrM) to immune checkpoint blockade (ICB) is less well studied. Here, we present an integrated single-cell RNA-Seq (scRNA-Seq) study of 19 ICB-naive and 9 ICB-treated BrM samples from our own and published data sets. We compared them with our previously published scRNA-Seq data from rGBM and found that ICB led to more prominent T cell infiltration into BrM than rGBM. These BrM-infiltrating T cells exhibited a tumor-specific phenotype and displayed greater activated/exhausted features. We also used multiplex immunofluorescence and spatial transcriptomics to reveal that ICB reduced a distinct CD206+ macrophage population in the perivascular space, which may modulate T cell entry into BrM. Furthermore, we identified a subset of progenitor exhausted T cells that correlated with longer overall survival in BrM patients. Our study provides a comprehensive immune cellular landscape of ICB’s effect on metastatic brain tumors and offers insights into potential strategies for improving ICB efficacy for brain tumor patients.
- 1 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (17)
Open AccessImmune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
In comparison with responses in recurrent glioblastoma (rGBM), the intracranial response of brain metastases (BrM) to immune checkpoint blockade (ICB) is less well studied. Here, we present an integrated single-cell RNA-Seq (scRNA-Seq) study of 19 ICB-naive and 9 ICB-treated BrM samples from our own and published data sets. We compared them with our previously published scRNA-Seq data from rGBM and found that ICB led to more prominent T cell infiltration into BrM than rGBM. These BrM-infiltrating T cells exhibited a tumor-specific phenotype and displayed greater activated/exhausted features. We also used multiplex immunofluorescence and spatial transcriptomics to reveal that ICB reduced a distinct CD206+ macrophage population in the perivascular space, which may modulate T cell entry into BrM. Furthermore, we identified a subset of progenitor exhausted T cells that correlated with longer overall survival in BrM patients. Our study provides a comprehensive immune cellular landscape of ICB’s effect on metastatic brain tumors and offers insights into potential strategies for improving ICB efficacy for brain tumor patients.
- Open Access
- 24 April 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (6) , 941-954
High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
The range of vaccines developed against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) provides a unique opportunity to study immunization across different platforms. In a single-center cohort, we analyzed the humoral and cellular immune compartments following five coronavirus disease 2019 (COVID-19) vaccines spanning three technologies (adenoviral, mRNA and inactivated virus) administered in 16 combinations. For adenoviral and inactivated-virus vaccines, heterologous combinations were generally more immunogenic compared to homologous regimens. The mRNA vaccine as the second dose resulted in the strongest antibody response and induced the highest frequency of spike-binding memory B cells irrespective of the priming vaccine. Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. Distinct immune signatures were elicited by the different vaccine combinations, demonstrating that the immune response is shaped by the type of vaccines applied and the order in which they are delivered. These data provide a framework for improving future vaccine strategies against pathogens and cancer.
- 24 April 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (6) , 941-954
Open AccessHigh-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
The range of vaccines developed against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) provides a unique opportunity to study immunization across different platforms. In a single-center cohort, we analyzed the humoral and cellular immune compartments following five coronavirus disease 2019 (COVID-19) vaccines spanning three technologies (adenoviral, mRNA and inactivated virus) administered in 16 combinations. For adenoviral and inactivated-virus vaccines, heterologous combinations were generally more immunogenic compared to homologous regimens. The mRNA vaccine as the second dose resulted in the strongest antibody response and induced the highest frequency of spike-binding memory B cells irrespective of the priming vaccine. Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. Distinct immune signatures were elicited by the different vaccine combinations, demonstrating that the immune response is shaped by the type of vaccines applied and the order in which they are delivered. These data provide a framework for improving future vaccine strategies against pathogens and cancer.
- Open Access
- 12 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33677
Lumbar Epidural Cavernous Hemangioma: A Case Report and Review of the Literature
Pure epidural cavernous hemangioma (ECH) of the spine are rare and account for only 4% of all epidural spinal lesions. We report a case of epidural cavernoma at L3/4 presenting with L4 radiculopathy. Radiological, intraoperative findings and histopathology are presented. We present the case of a 56-year-old man who was admitted with a right L4 radiculopathy including an M4 paresis of the right leg, hypoesthesia L4, and radicular pain. Magnetic resonance imaging (MRI) confirmed an extradural lesion L3/4 partially expanding into the right intervertebral foramen. The lesion had a heterogeneous signal, isointense on T1-weighted and hyperintense on proton density (PD) and T2-weighted images. At surgery, an epidural, ovoid, gray-red, soft mass, lightly adherent to the dura and extending to the right L4 foramen was observed. Findings in the histological examination indicated a cavernous hemangioma without signs of hemorrhage. Symptoms and paresis improved rapidly after surgery. The follow-up MRI showed complete resection of the lesion with no signs of radicular compression. Spinal ECH should be considered as a cause of chronic lumbar radiculopathy with atypical radiological findings. Early diagnosis and total removal of the spinal ECH might prevent hemorrhage and neurological deficits. Fewer than 50 cases of lumbar epidural spinal hemangioma have been reported until today, and our case report is adding valuable knowledge to the existing literature.
- 12 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33677
Open AccessLumbar Epidural Cavernous Hemangioma: A Case Report and Review of the Literature
Pure epidural cavernous hemangioma (ECH) of the spine are rare and account for only 4% of all epidural spinal lesions. We report a case of epidural cavernoma at L3/4 presenting with L4 radiculopathy. Radiological, intraoperative findings and histopathology are presented. We present the case of a 56-year-old man who was admitted with a right L4 radiculopathy including an M4 paresis of the right leg, hypoesthesia L4, and radicular pain. Magnetic resonance imaging (MRI) confirmed an extradural lesion L3/4 partially expanding into the right intervertebral foramen. The lesion had a heterogeneous signal, isointense on T1-weighted and hyperintense on proton density (PD) and T2-weighted images. At surgery, an epidural, ovoid, gray-red, soft mass, lightly adherent to the dura and extending to the right L4 foramen was observed. Findings in the histological examination indicated a cavernous hemangioma without signs of hemorrhage. Symptoms and paresis improved rapidly after surgery. The follow-up MRI showed complete resection of the lesion with no signs of radicular compression. Spinal ECH should be considered as a cause of chronic lumbar radiculopathy with atypical radiological findings. Early diagnosis and total removal of the spinal ECH might prevent hemorrhage and neurological deficits. Fewer than 50 cases of lumbar epidural spinal hemangioma have been reported until today, and our case report is adding valuable knowledge to the existing literature.
- Open Access
- 1 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , vii137
IMMU-27. SIMULTANEOUS TARGETING OF THE PD-L1 AND THE TGF-Β PATHWAYS WITH BINTRAFUSP ALFA IN EXPERIMENTAL GLIOMAS
Currently, immunotherapy is one of the most promising research areas in oncology, but immunotherapeutic strategies do not have proven clinical activity against glioblastoma so far. The immunosuppressive microenvironment of gliomas limits an appropriate anti-tumor immune response and represents a major challenge in the context of immunotherapy. Therefore, novel therapeutic strategies that reactivate the immune system and allow for potent anti-glioma immune responses are needed. Bintrafusp alfa is a bifunctional fusion protein that is composed of the extracellular domain of human transforming growth factor-beta receptor type II (TGF-βRII) and a human IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1). It is designed to target the TGF-β and the PDL-1 pathways simultaneously by specifically localizing to the tumor via the anti-PD-L1 moiety and sequestering TGF-β within the tumor microenvironment. We analyzed interrelations between the immunosuppressive factors TGF-β and PD-L1 in glioblastoma samples from patients and observed a significant correlation that points towards a co-regulation of both targets as part of a gene expression network. Next, we assessed the activity of bintrafusp alfa in human and murine glioma cell lines in vitro and observed interference with TGF-β-induced Smad2 phosphorylation as a bona fide response marker of TGF-β pathway activation and an increase in immune cell-mediated glioma cell killing. In vivo, bintrafusp alfa prolonged the survival of glioma-bearing immunocompetent mice, whereas the survival benefit was absent in immunodeficient Rag1-/- mice lacking T and B cell populations. Characterization of the tumor microenvironment by immunohistochemistry and high-dimensional flow cytometry confirmed the immune-activating effects of bintrafusp alfa. In summary, these encouraging results demonstrate that novel treatment options such as bintrafusp alfa may have the potential to overcome the lack of immunogenicity and reinvigorate anti-tumor immune responses to efficiently combat glioblastoma.
- 1 November 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 24 (Supplement) , vii137
Open AccessIMMU-27. SIMULTANEOUS TARGETING OF THE PD-L1 AND THE TGF-Β PATHWAYS WITH BINTRAFUSP ALFA IN EXPERIMENTAL GLIOMAS
Currently, immunotherapy is one of the most promising research areas in oncology, but immunotherapeutic strategies do not have proven clinical activity against glioblastoma so far. The immunosuppressive microenvironment of gliomas limits an appropriate anti-tumor immune response and represents a major challenge in the context of immunotherapy. Therefore, novel therapeutic strategies that reactivate the immune system and allow for potent anti-glioma immune responses are needed. Bintrafusp alfa is a bifunctional fusion protein that is composed of the extracellular domain of human transforming growth factor-beta receptor type II (TGF-βRII) and a human IgG1 monoclonal antibody blocking programmed death-ligand 1 (PD-L1). It is designed to target the TGF-β and the PDL-1 pathways simultaneously by specifically localizing to the tumor via the anti-PD-L1 moiety and sequestering TGF-β within the tumor microenvironment. We analyzed interrelations between the immunosuppressive factors TGF-β and PD-L1 in glioblastoma samples from patients and observed a significant correlation that points towards a co-regulation of both targets as part of a gene expression network. Next, we assessed the activity of bintrafusp alfa in human and murine glioma cell lines in vitro and observed interference with TGF-β-induced Smad2 phosphorylation as a bona fide response marker of TGF-β pathway activation and an increase in immune cell-mediated glioma cell killing. In vivo, bintrafusp alfa prolonged the survival of glioma-bearing immunocompetent mice, whereas the survival benefit was absent in immunodeficient Rag1-/- mice lacking T and B cell populations. Characterization of the tumor microenvironment by immunohistochemistry and high-dimensional flow cytometry confirmed the immune-activating effects of bintrafusp alfa. In summary, these encouraging results demonstrate that novel treatment options such as bintrafusp alfa may have the potential to overcome the lack of immunogenicity and reinvigorate anti-tumor immune responses to efficiently combat glioblastoma.
- Open Access
- 30 September 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (10) , 1326
Adaptive Hybrid Surgery Experiences in Benign Skull Base Tumors
Background: The treatment of benign skull base tumors remains challenging. These tumors are often located in close relationship to critical structures. Therefore, radical resection of these tumors can be associated with high morbidity. Multimodal treatment concepts, including controlled partial tumor resection followed by radiosurgery, should be considered. Methods: Adaptive hybrid surgery analysis (AHSA) is an intraoperative tool that has been introduced for the automatic assessment of tumor properties, and virtual real-time radiosurgical treatment simulation and continuous feasibility analysis of adjuvant radiosurgery. The AHSA method (Brainlab®, Munich, Germany) was applied to five patients who underwent partial resection of a benign skull base tumor. Tumor volumetry was obtained on pre- and postoperative MR scans. Organs at risk were, preoperative, automatically delineated with atlas mapping software (Elements® Segmentation Cranial), and adaptations were made if necessary. Results: Five patients with benign skull base lesions underwent planned partial tumor resection in a multimodal therapeutic surgery followed by radiosurgery. The preoperative tumor volumes ranged between 8.52 and 25.2 cm3. The intraoperative residual tumor volume measured with the AHSA® software ranged between 2.13–12.17 cm3 (25–52% of the preoperative tumor volume). The intraoperative automatic AHSA plans of the remaining tumor volume suggested, in all five patients, that safe hypofractionated radiation was feasible. Patients were followed for 69.6 ± 1.04 months, and no complications occurred after the patients were treated with radiation. Conclusions: Intraoperative SRS planning based on volumetric assessments during resection of skull base tumors using AHSA® is feasible and safe. The AHSA method allows the neurosurgeon to continuously evaluate the feasibility of adjuvant radiosurgery while planning and performing a surgical resection. This method supports the treatment strategy of a complementary approach during surgical resection of complex skull base tumors and might contribute to preventing surgical and radiosurgical complications.
- 30 September 2022
- Published by MDPI AG in Brain Sciences
- Vol. 12 (10) , 1326
Open AccessAdaptive Hybrid Surgery Experiences in Benign Skull Base Tumors
Background: The treatment of benign skull base tumors remains challenging. These tumors are often located in close relationship to critical structures. Therefore, radical resection of these tumors can be associated with high morbidity. Multimodal treatment concepts, including controlled partial tumor resection followed by radiosurgery, should be considered. Methods: Adaptive hybrid surgery analysis (AHSA) is an intraoperative tool that has been introduced for the automatic assessment of tumor properties, and virtual real-time radiosurgical treatment simulation and continuous feasibility analysis of adjuvant radiosurgery. The AHSA method (Brainlab®, Munich, Germany) was applied to five patients who underwent partial resection of a benign skull base tumor. Tumor volumetry was obtained on pre- and postoperative MR scans. Organs at risk were, preoperative, automatically delineated with atlas mapping software (Elements® Segmentation Cranial), and adaptations were made if necessary. Results: Five patients with benign skull base lesions underwent planned partial tumor resection in a multimodal therapeutic surgery followed by radiosurgery. The preoperative tumor volumes ranged between 8.52 and 25.2 cm3. The intraoperative residual tumor volume measured with the AHSA® software ranged between 2.13–12.17 cm3 (25–52% of the preoperative tumor volume). The intraoperative automatic AHSA plans of the remaining tumor volume suggested, in all five patients, that safe hypofractionated radiation was feasible. Patients were followed for 69.6 ± 1.04 months, and no complications occurred after the patients were treated with radiation. Conclusions: Intraoperative SRS planning based on volumetric assessments during resection of skull base tumors using AHSA® is feasible and safe. The AHSA method allows the neurosurgeon to continuously evaluate the feasibility of adjuvant radiosurgery while planning and performing a surgical resection. This method supports the treatment strategy of a complementary approach during surgical resection of complex skull base tumors and might contribute to preventing surgical and radiosurgical complications.